Statins: who genuinely benefits, who probably doesn't

Statins are simultaneously one of the best-evidenced cardiovascular drugs in pharmacology, and one of the most over-prescribed primary-prevention interventions of the last twenty years. Both statements are true. The frame that resolves the contradiction is risk stratification: the benefit per person scales with their baseline cardiovascular risk, and so does the math on whether it's worth taking the pill.

The strong case: secondary prevention

If you have had a heart attack, stroke, or established atherosclerotic cardiovascular disease, the question is not "should I take a statin." It's "which statin and how high a dose." The evidence here is among the cleanest in any drug class:

• The Cholesterol Treatment Trialists' Collaboration meta-analyses, drawing from 28+ randomized trials covering hundreds of thousands of patients, show consistent absolute risk reductions for major cardiovascular events.^[1] Evidence: A
• The effect is linear with LDL/ApoB lowering: each 1 mmol/L (~39 mg/dL) reduction in LDL-C lowers major event risk by roughly 21-22% per year of treatment.
• High-intensity statins (atorvastatin 40-80, rosuvastatin 20-40) outperform moderate-intensity in this group.

This is the cleanest application. Anyone in this category who refuses statins on the basis of internet skepticism is taking a meaningfully worse statistical bet.

The reasonable case: high-risk primary prevention

For people who haven't had an event but whose risk is plausibly high:

• ApoB persistently elevated despite lifestyle (e.g. >130 mg/dL on a thoughtful diet)
• Lp(a) >75-100 nmol/L
• Coronary artery calcium score above the 75th percentile for age
• Strong family history of premature cardiovascular disease
• Familial hypercholesterolemia
• Established type 2 diabetes plus other risk factors

For these patients, the absolute risk reduction is smaller than secondary prevention but still meaningful, often 2-4 events prevented per 100 patients treated for 5-10 years.^[2] Evidence: A The decision is straightforward when the risk picture is genuinely elevated.

The harder case: low-risk primary prevention

This is where the prescribing patterns and the math diverge.

For a 45-year-old non-smoker with normal blood pressure, no family history, normal weight, a normal-ish CAC score, and an LDL-C of 130 mg/dL:

• The relative risk reduction from a statin is similar (~20-25% per year).
• The absolute event rate without a statin is low (maybe 5-7% over ten years).
• The absolute benefit shrinks to roughly 1-1.5% over ten years.
• The probability of muscle symptoms, new-onset type 2 diabetes, or other side effects remains roughly constant.

In this person, the math becomes a genuine value call, not a clear positive. The Number Needed to Treat (NNT) to prevent one major event rises into the 50-100 range over 5 years for very low-risk populations.^[3] Reasonable people, including thoughtful cardiologists, disagree on where the line is. Evidence: B for "statins reduce risk in this group"; Evidence: C for "the absolute benefit clears the side-effect threshold for every low-risk patient."

The dishonest framing in either direction:

• "Statins are over-prescribed and barely work" misses the secondary-prevention case entirely.
• "Everyone over 40 should take a statin" applies population-average benefit to individuals whose absolute risk doesn't justify it.

Side effects: real, but smaller and larger than the polarized takes

Muscle symptoms. Self-reported myalgia is common, in the range of 5-20% in surveys, but blinded N-of-1 trials are sobering. The SAMSON trial randomized patients with self-reported statin intolerance to alternating months of statin, placebo, and no pill; symptoms were nearly identical on statin and placebo, and most patients went back on the drug afterward.^[4] The nocebo effect is substantial. That said, real statin-induced myopathy exists in a small fraction of patients, and rare severe rhabdomyolysis (~1 case per 10,000-100,000 patient-years) is real. Evidence: A for the existence of nocebo and the rarity of severe harm; Evidence: B for population-level prevalence of true myopathy.

New-onset type 2 diabetes. This is real. Statins (particularly high-intensity rosuvastatin and atorvastatin) increase incident type 2 diabetes in susceptible patients by ~10-25% relative risk in meta-analyses, equivalent to about 1 additional case per 250-500 patient-years.^[5] Almost all of this risk falls on patients who were near the diabetes threshold anyway; statins probably accelerate a course that was already in motion. Evidence: A

Cognitive symptoms. Alleged in observational reports, but not supported in the trial data. Large RCTs do not show meaningful cognitive decline; the FDA's 2012 warning has not been substantiated in subsequent rigorous research.^[6] Evidence: B for "no meaningful effect."

Liver enzymes. Small, transient elevations are common; clinically significant liver injury is rare. Routine liver-enzyme monitoring is no longer recommended for most patients.^[7]

The most useful single test, if you're trying to decide

For a patient over 40 who isn't a clear secondary-prevention case, a coronary artery calcium (CAC) score does more work than any blood test.

• A CAC score of zero in a 50+ year old is one of the strongest favorable risk signals in cardiovascular medicine: 10-year event rates fall below 1%, and the absolute benefit of statins in that group is very small.
• A high CAC for age (>75th percentile, or any score over 100 in someone under 55) tilts the math toward statins regardless of LDL-C.

If you're trying to make the call honestly, get an ApoB, an Lp(a), and a CAC score. Those three numbers, plus age, blood pressure, and family history, do more than the standard lipid panel ever will.

The natural-alternative question

• Red yeast rice is monacolin K, which is chemically lovastatin. Same mechanism, same side effects, but with much less dose control because the product is a fermented extract. Treating it as "not a statin" is wrong.
• Berberine has modest LDL-lowering effects in small trials. Not in the same effect-size league as a moderate statin dose.
• Plant sterols, soluble fiber, monacolin-free supplements: modest 5-15% LDL reductions. Useful as add-ons, not replacements for indicated therapy.
• Ezetimibe (a non-statin LDL-lowering drug) has solid outcome trial evidence and is a reasonable option for statin-intolerant patients or as an add-on.^[2]

The takeaway: if a statin is clearly indicated and you don't want one, the alternative isn't a supplement, it's a real conversation with a clinician about the alternatives that have outcome data (ezetimibe, PCSK9 inhibitors, bempedoic acid).

The practical decision tree

1. Have you had a cardiovascular event? Take the statin. The math is clear.
2. Do you have FH, very high Lp(a), or an abnormal CAC for age? Take the statin (or another LDL-lowering therapy). The math is good.
3. Are you 50+ with normal-ish lipids but uncertain risk? Get a CAC score. A score of zero buys you confidence; a high score changes the call.
4. Are you 30-45, lean, athletic, normal blood pressure, no family history, and the only flag is an LDL number? First, get ApoB and Lp(a). If both are reassuring, the case for a statin is thin. If ApoB is genuinely elevated for your age, the conversation is real.
5. Are you adopting a low-carb or animal-based diet and seeing LDL rise? Read the ApoB and lipid debate. Don't make the decision off LDL-C alone.

The honest position: statins are a powerful tool that works extremely well for some people and gets oversold for others. Where the math is good, the drug is a near-no-brainer. Where the math is marginal, the decision is reasonably yours, with your clinician, on the basis of the full picture rather than a single number.

FAQ

Are statins effective? Secondary prevention: yes, robustly. High-risk primary: yes. Low-risk primary: smaller absolute benefit; reasonable people disagree.

What about side effects? Muscle symptoms are common but heavily nocebo-mediated; new-onset type 2 diabetes is a real ~10-25% relative increase in susceptible patients; rare severe harm exists but is rare.

Natural alternatives? Red yeast rice IS a statin. Berberine, sterols, fiber: modest. For indicated patients, ezetimibe is the real non-statin alternative with outcome data.

References

1. 1.Cholesterol Treatment Trialists' (CTT) Collaboration (2019). Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet 393(10170):407–415. PMID: 30712900. Link
2. 2.Cannon CP, et al. (IMPROVE-IT) (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine 372(25):2387–2397. PMID: 26039521. Link
3. 3.Ridker PM, et al. (JUPITER) (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 359(21):2195–2207. PMID: 18997196. Link
4. 4.Wood FA, et al. (SAMSON) (2020). N-of-1 trial of a statin, placebo, or no treatment to assess side effects. New England Journal of Medicine 383(22):2182–2184. PMID: 33196154. Link
5. 5.Sattar N, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 375(9716):735–742. PMID: 20167359. Link
6. 6.Ott BR, et al. (2015). Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of General Internal Medicine 30(3):348–358. PMID: 25575908. Link
7. 7.Bays H, et al. (2014). An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology 8(3 Suppl):S47–S57. PMID: 24793443. Link